1201923-48-9

Basic information

• Product Name: 1,1-dimethylethyl {(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}carbamate
• Synonyms: 1,1-dimethylethyl {(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}carbamate;(S)-tert-butyl 1-(1,3-dioxoisoindolin-2-yl)-3-(3-fluorophenyl)propan-2-ylcarbamate
• CAS NO: 1201923-48-9
• Molecular Formula: C₂₂H₂₃FN₂O₄
• Molecular Weight: 398.4274232
• Mol File: 1201923-48-9.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 1,1-dimethylethyl {(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: 1,1-dimethylethyl {(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}carbamate(1201923-48-9)
• EPA Substance Registry System: 1,1-dimethylethyl {(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}carbamate(1201923-48-9)

Safety Data

• Hazardous Substances Data: 1201923-48-9(Hazardous Substances Data)

Usage

Chemical structure

A complex chemical compound with multiple functional groups and a chiral center.

Chiral center

Exists as a single stereoisomer with a chiral center at the 1S position.

Functional groups

Contains a 1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl group, a (3-fluorophenyl)methyl group, and an ethyl carbamate moiety.

Fluorophenyl group

Presence of a fluorophenyl group, which is commonly associated with biological activity in pharmaceutical compounds.

Potential applications

May have potential applications in the fields of medicine, pharmacology, and drug development due to its complex structure and the presence of a fluorophenyl group.

Biological activity

Likely to have pharmaceutical or biological activity due to its complex structure and the presence of a fluorophenyl group.

Stereochemistry

The compound has a specific stereochemistry, with the chiral center at the 1S position.

Upstream product

• 136918-14-4 phthalimide 
• 944470-56-8 tert-butyl [(1S)-1-(3-fluorobenzyl)-2-hydroxyethyl]carbamate 
• 114873-01-7 N-Boc-3-fluoro-L-phenylalanine 

Downstream Products

• 1202237-87-3 2-[(2S)-2-amino-3-(3-fluorophenyl)propyl]-1H-isoindole-1,3(2H)-dione hydrochloride 
• 1047644-62-1 N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl] ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide 
• 1047645-80-6 5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-N-{(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}-2-thiophenecarboxamide 
• 943325-38-0 2-[(2S)-2-amino-3-(3-fluorophenyl)propyl]-1H-isoindole-1,3(2H)-dione 
• 1430058-15-3 C₃₅H₂₇FN₄O₃ 
• 1430058-14-2 C₃₀H₂₂FN₅O₃ 
• 1430057-35-4 2-[(1S)-2-amino-1-(3-fluorobenzyl)ethyl]-6-(4-chloro-1-methyl-1H-pyrazol-5-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one 
• 1430058-68-6 2-[(2S)-2-(6-chloro-3-oxo-1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-3-(3-fluorophenyl)propyl]-1H-isoindole-1,3(2H)-dione 
• 1430056-55-5 2-[(1S)-2-amino-1-(3-fluorobenzyl)ethyl]-5-(4-phenyl-1-methyl-1H-pyrazol-5-yl)isoindolin-1-one 
• 1430056-54-4 2-[(1S)-2-amino-1-(3-fluorobenzyl)ethyl]-5-(4-cyano-1-methyl-1H-pyrazol-5-yl)isoindolin-1-one 
• 1430056-53-3 2-[(1S)-2-amino-1-(3-fluorobenzyl)ethyl]-5-(4-bromo-1-methyl-1H-pyrazol-5-yl)isoindolin-1-one 
• 1430058-13-1 2-[(2S)-2-[5-(4-bromo-1-methyl-1H-pyrazol-5-yl)-1-oxo-1,3-dihydro-2H-isoindol-2-yl]-3-(3-fluorophenyl)propyl]-1H-isoindole-1,3(2H)-dione 
• 1430056-52-2 2-[(1S)-2-amino-1-(3-fluorobenzyl)ethyl]-5-(4-fluoro-1-methyl-1H-pyrazol-5-yl)isoindolin-1-one 
• 1430058-12-0 2-[(2S)-2-[5-(4-fluoro-1-methyl-1H-pyrazol-5-yl)-1-oxo-1,3-dihydro-2H-isoindol-2-yl]-3-(3-fluorophenyl)propyl]-1H-isoindole-1,3(2H)-dione 

Relevant articles and documents

AFURESERTIB: Protein kinase B (PKB) inhibitor Oncolytic

The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway plays key roles in cellular proliferation and survival. Mutations and alterations in this signal transduction pathway have been described in a variety of solid and hematopoietic malignancies, which may contribute to perpetuation of the disease in a number of ways. Increasing interest in targeting particular facets of this signaling cascade has led to the development of a number of novel anticancer agents, including afuresertib (GSK-2110183), an orally bioavailable pan-inhibitor of the RAC-alpha serine/threonine protein kinase, also referred to as protein kinase B or proto-oncogene c-Akt. The present review summarizes the preclinical and pharmacological aspects of afuresertib and early clinical experience.

PYRIDO PYRIMIDINES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.

INHIBITORS OF AKT ACTIVITY

Invented are novel hetero-pyrrole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.